{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-009506","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.675253+00:00","generated_at":"2026-06-05T14:39:32.057901+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rocket Pharma Reports Q4 2023 Net Loss of $59.7M; PDUFA Date for KRESLADI Set for June 30, 2024","bullets":["Cash, cash equivalents and investments stood at $407.5M as of Dec 31, 2023, providing runway into 2026.","Net loss for Q4 2023 was $59.7M ($0.64 per share); full year 2023 net loss $245.6M ($2.92 per share).","FDA extended Priority Review of KRESLADI BLA for severe LAD-I to June 30, 2024; no advisory committee needed.","Fanconi Anemia BLA and MAA filings remain on track for H1 2024; pipeline milestones for 2024 reaffirmed.","Appointed R. Keith Woods to Board; he previously led commercialization of Vyvgart at argenx."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-009506","json":"https://secwatch.observer/filing/0001140361-24-009506.json","markdown":"https://secwatch.observer/filing/0001140361-24-009506.md","text":"https://secwatch.observer/filing/0001140361-24-009506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/0001140361-24-009506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/ef20022436_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T14:39:32.057901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6412d82c844b0c26d35f105f99ea9e0541e7e754","claim":"ROCKET PHARMACEUTICALS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve, EPS $0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023.","evidence_excerpt":"Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/0001140361-24-009506-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve"},{"label":"EPS","value":"$0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}